Table 3.
Cumulative radiological response among patients treated with atezolizumab-bevacizumab among CTP A and B.
| RECIST |
P | mRECIST |
P | |||
|---|---|---|---|---|---|---|
| CTP A | CTP B | CTP A | CTP B | |||
| ORR | 25.9% (22.7–29.4; 180/698) | 16.8% (12–31.6; 14/83), | 0.07 | 33.6% (28–40.1; 83/247) | 30% (15.4–54.5; 17/57) | 0.58 |
| DCR | 78.4% (75–81.1; 547/698) | 68% (57–77.3; 57/83) | 0.04 | 81% (75.6–85.5; 201/247) | 67% (53.5–78; 38/57) | 0.01 |
| CR | 3.2% (17/522) | 0% (0/62) | 0.14 | 9.8% (7/71) | 13.9% (5/36) | 0.53 |
| PR | 24.1% (126/522) | 22.6% (14/62) | 0.78 | 28.2% (20/71) | 27.8% (10/36) | 0.96 |
| SD | 51.7% (311/602) | 46.7% (35/75) | 0.41 | 48.4% (73/151) | 34.7% (17/49) | 0.09 |
| PD | 21.4% (129/602) | 33.4% (25/75) | 0.02 | 15.2% (23/151) | 34.7% (17/49) | 0.003 |
RECIST, Response Criteria evaluation in solid tumour; mRECIST, modified RECIST; ORR-Objective response rate; DCR, Disease Control Rate; CR, Complete Response; PR, Partial response; SD, Stable Disease; PD, Progressive Disease.